PharmaCielo Ltd. Appoints Medical Advisory Board
(Thomson Reuters ONE) -
TORONTO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Dr. Patricio Stocker, President and
CEO of PharmaCielo Ltd., announced the company has appointed a Medical Advisory
Board (MAB) to provide guidance on the development of medicinal-grade cannabis
oil extracts and related products appropriate for use by clinical practitioners.
"Under the guidance of Dr. Delon Human, PharmaCielo Board of Directors member
and Chair of the MAB, appointees will be able to provide significant input in
the development of our medicinal-grade products through their ability to provide
global expertise in the areas of healthcare policy, regulation, medical science
and patient insights in addition to their clinical experience," said Dr.
Stocker.
Dr. Human has assembled an experienced team of international medical clinicians
whose expertise will be leveraged to provide guidance in the development of
medicinal-grade cannabis oil based products, as well as international insight
and understanding of worldwide healthcare policy and its implications for this
emerging global industry.
"The Medical Advisory Board will oversee PharmaCielo's practices and processes,
ensuring they are UN-aligned and performed ethically and according to Good
Manufacturing and Good Medical Practice," said Dr. Human. "During the April
2016 UN General Assembly Special Session on Drugs, the UN and its member states
strongly endorsed the need to ensure the accessibility and availability of
internationally controlled drugs for medical and scientific purposes, including
substances such as cannabinoids. In developing a global framework, this should
be promoted within national legal systems, while simultaneously preventing
diversion, abuse and trafficking. PharmaCielo has the opportunity to develop the
world's finest quality, naturally grown, pharma-grade cannabis oils."
Four appointees to the MAB were introduced (full biographies are available
at www.pharmacielo.com):
Dr. Delon Human, M.B.Ch.B., M.Prax.Med., MFGP, DCH, MBA
Member, PharmaCielo Board of Directors; Chair, Medical Advisory Board
Dr. Delon Human is the president and CEO of Health Diplomats, a health advisory
and consulting practice, providing strategic and technical advice on global
health issues to Fortune 500 companies in the pharmaceutical, food, tobacco,
nicotine and medical device industries as well as NGOs, governments and
foundations. He has acted as adviser to WHO Director-Generals and UN Secretary-
General Ban Ki Moon.
He is a published author and specializes in global health strategy, corporate
and product transformation, harm reduction and health communication. Formerly,
he served as the Secretary-General of the International Food and Beverage
Alliance (IFBA), which brings together the top food companies in the world.
From 1997 to 2005, Dr. Human served as secretary general of the World Medical
Association (WMA), the global representative body for physicians. He was
instrumental in the establishment of the World Health Professions Alliance, an
alliance of the global representative bodies of physicians, nurses, pharmacists,
dentists and physical therapists.
Dr. Human qualified as a physician in South Africa and completed his
postgraduate studies in family medicine and child health in South Africa and
Oxford, England. He was a clinician for two decades, part of the pediatric
endocrinology research unit at the John Radcliffe Hospital and was involved in
the establishment of several medical centers, a hospital and emergency clinic in
South Africa. His business studies (MBA) were completed at the Edinburgh
Business School.
Dr. Anders Milton, MD, PhD, Member, Medical Advisory Board
A former chair of the World Medical Association, Dr. Anders Milton is a highly
sought-after consultant within the healthcare sector and has served as president
of the European Regional Network on HIV/AIDS (ERNA) and as president of the
Swedish Red Cross among a number of other positions, including appointment by
the Swedish government as chairman of a committee on Swedish HIV/AIDS policies
and a member of the Catastrophe Commission formed following the December 2004
tsunami. Recently he led a select committee studying organ donation and
transplantation.
Previously, Dr. Milton served as president and CEO of the Swedish Medical
Association.
A director of several public and privately held companies and foundations, Dr.
Milton originally studied economics before turning to medicine, and after
graduating university as a medical doctor and PhD he served as a clinician at
the Department of Nephrology at the University Hospital at Uppsala. Throughout
his career he has been engaged in work in support of human rights, ethics of
medical practice and safe health care, of which effective pharmacotherapy is an
integral part.
Dr. Juan E. Gutiérrez, MD, Member, Medical Advisory Board
Dr. Gutiérrez is a neuroradiologist in private practice and Director of the
Neuroradiology Division at Centro Avanzado de Diagnostíco Médico (CEDIMED) in
Colombia.
Previously, Dr. Gutiérrez served at the University of Texas Health Science
Center in San Antonio, TX as Associate Professor of Radiology, Vice Chair of
Clinical Operations, Medical Director and Director of the Clinical Trials
Division at the Radiology Department. He was formerly Director of Medical
Development, Diagnostic Imaging and Associate Director of Clinical Development,
Diagnostic Imaging for Bayer Healthcare (formerly Berlex Laboratories) in
Montville, NJ. Dr. Gutiérrez also served as a medical monitor with Novartis
(formerly Ciba-Geigy Labs) in Medellin.
Dr. Gutiérrez has been the recipient of several awards for his work, and has
been the lead researcher, international researcher and co-investigator on
numerous clinical trials. Regularly published, he has co-edited five medical
books and authored or co-authored over 25 book chapters as well as 17 peer-
reviewed articles and scores of abstracts and articles published in scientific
research journals.
Dr. Gutiérrez received a Doctorate in Medicine and Surgery from CES University
in Medellin and Specialist in Clinical Radiology from Pontifical Xavierian
University / San Ignacio Hospital in Bogota. He completed a research fellowship
in Neuroradiology at Thomas Jefferson University / TJU Hospital in Philadelphia,
PA and a visiting fellowship in Interventional Neuroradiology at the University
of Miami / Jackson Memorial Hospital.
Jorge Andrés Soto, MD, Member, Medical Advisory Board
Dr. Soto is Chairman of the Department of Radiology at Boston Medical Center and
a Professor of Radiology at the Boston University School of Medicine. He has
previously served as a general medical practitioner with the Hospital San
Antonio de Prado in Colombia, section head of Body Imaging at University of San
Vicente de Paúl Hospital, radiologist at CEDIMED in Medellin, assistant
professor of Radiology at the University of Antioquia and was vice chairman of
Boston Medical Center's Department of Radiology for ten years.
A native of Medellin with citizenship in both Colombia and the United States,
Dr. Soto received his Doctor in Medicine and Surgery and Specialist in
Diagnostic Radiology from CES University's Health Sciences Institute in
Medellin, and completed a Radiology Body Imaging Fellowship at Boston University
Medical Center.
Dr. Soto has received honors and awards from the Colombian Ministry of
Education, Medellin Medicine Academy, Boston University Medical Center and
numerous professional societies. An extensively published researcher, Dr. Soto
is a member of the editorial boards of Radiology and Abdominal Imaging, has
edited seven books and has published over 85 original research papers and more
than 35 reviews, book chapters and case reports.
About PharmaCielo Ltd:
PharmaCielo Ltd. (the "Company") is a global company privately held and
headquartered in Canada, with a focus on processing and supplying all natural,
medicinal-grade cannabis oil extracts and related products to large channel
distributors. The Company's principal (and wholly-owned) subsidiary is
PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and
Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo
Colombia Holdings are comprised of a diversely talented group of international
business executives and specialists with relevant and varied expertise.
PharmaCielo recognized the significant role that Colombia's ideal location will
play in building a sustainable business in the medical cannabis industry, and
the Company, together with its directors and executives, has built a compelling
business plan focused on supplying the international marketplace.
For further information:
www.PharmaCielo.com
Media Relations:
David Gordon, Tel: +1 647 259 3258, David.Gordon(at)CohnWolfe.ca
(Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776,
Juan.M.Cuellar(at)Sprgroup.biz
Investor Inquiries:
Tel: +1 647 560 4640, Toll Free 888 968 8279, Investors(at)PharmaCielo.com
This press release contains forward-looking statements. Often, but not always,
forward-looking statements can be identified by the use of words such as
"plans", "expects" or "does not expect", "is expected", "estimates", "intends",
"anticipates" or "does not anticipate", or "believes", or "recurring" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur or be
achieved. Forward-looking statements involve known and unknown risks,
uncertainties and other factors, such as demand for the Company's products,
currency exchange changes and risks, internal funding and the financial
condition of the Company, product roll-out, competition, technological changes,
and other commercial matters involving the Company, its products, and the
markets in which the Company operates, as well as general economic conditions,
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Actual results and
developments are likely to differ, and may differ materially, from those
expressed or implied by the forward-looking statements contained in this press
release. There can be no assurance that forward-looking statements will prove to
be accurate, as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
events or otherwise. However, any further disclosures made on related subjects
in subsequent reports should be consulted.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PharmaCielo via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 30.11.2016 - 19:40 Uhr
Sprache: Deutsch
News-ID 510107
Anzahl Zeichen: 12508
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 325 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PharmaCielo Ltd. Appoints Medical Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
PharmaCielo (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
